— defines the composition of a structured clinical sequencing report (see Clause 5),

— defines the required data fields and their metadata for a structured clinical sequencing report (see Clause 6),

— defines the optional data (see Clause 7),

— covers the DNA-level variation from human samples using whole genome sequencing, whole exome sequencing, and targeted sequencing (disease-targeted gene panels) by next generation sequencing technologies. Though whole transcriptome sequencing and other technologies are important to provide better patient care and enable precision medicine, this document only deals with DNA-level changes,

— covers mainly clinical applications and clinical research such as clinical trials and translational research which uses clinical data. However, the necessary steps such as de-identification or consent from patient should be applied. The basic research and other scientific areas are outside the scope of this document,

— does not cover the other biological species, i.e. genomes of viruses and microbes, and

— does not cover the Sanger sequencing methods.